Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESICANS: Extracellular Vesicles During CAR-T Therapy and ICANS
2024-515328-35-00Phase 4Authorised
- Sponsor
- CHU Saint-Etienne
- Start
- Sep 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lisocabtagene maraleucel, axicabtagene ciloleucel, idecabtagene vicleucel, tisagenlecleucel and brexucabtagene autoleucel in hematopoietic malignancies, lymphoma, leukemia and 2 more, sponsored by CHU Saint-Etienne. Planned start Sep 2024; status: authorised.
02
Drugs
lisocabtagene maraleucelaxicabtagene ciloleucelidecabtagene vicleuceltisagenlecleucelbrexucabtagene autoleucel
03
Conditions
hematopoietic malignancieslymphomaleukemiamultiple myeloma (MM)immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on 2024-515328-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515328-35-00.